Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO-108 Monotherapy and Combination in Advanced Solid Tumors
NCT05508100Phase 1Completed
- Sponsor
- Immune-Onc Therapeutics
- Start
- Sep 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IO-108 in solid tumor (advanced stage) (3 arms), sponsored by Immune-Onc Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108 at 2 years, Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) in patients treated with IO-108 in combination with pembrolizumab or… at 2 years and 1 more. Started Sep 2022; status: completed.
02
Drugs
IO-108
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05508100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508100.